AimedBio, Boehringer Ingelheim Launch Phase 1 Trial of ADC Candidate

First patient dosed with BI 4060107
Milestone payment requirements under licensing agreement fulfilled

The antibody-drug conjugate (ADC) candidate discovered by AimedBio has entered Phase 1 clinical trials. The candidate was licensed to Boehringer Ingelheim in October last year, and its entry into this stage of clinical development has also fulfilled the contractual milestone payment requirements.

AimedBio announced on the 27th that the first patient has been dosed in the first-in-human Phase 1 trial of BI 4060107, which is being developed by Boehringer Ingelheim. The trial will evaluate dose-specific safety and tolerability in patients with advanced solid tumors.

AimedBio company logo image. AimedBio

BI 4060107 is a candidate developed using AimedBio's P-ADC platform for discovering new cancer drugs. It uses the ADC approach, in which a drug is attached to an antibody that targets cancer cells to induce an anticancer effect. The two companies signed a global collaboration and licensing agreement in October 2025, after which Boehringer Ingelheim took charge of clinical development.

AimedBio said BI 4060107 targets a molecule that is highly expressed in various types of cancer but has limited expression in normal tissues. The target is associated with tumor growth and metastasis, as well as treatment resistance.

With the achievement of this clinical development milestone, AimedBio has fulfilled the payment requirements under the agreement. The deal between the two companies is valued at up to $991 million (approximately KRW 1.3122 trillion), including an upfront payment and development, regulatory approval, and commercialization milestones, with separate royalties based on net sales. The amount of this milestone payment was not disclosed.

Heo Nam-gu, CEO of AimedBio, said, "Dosing the first patient is an important advance, as BI 4060107 moves from drug discovery to clinical evaluation. We will continue developing candidates for patients with hard-to-treat cancers." Vittoria Ginzala, Global Head of Experimental Medicine at Boehringer Ingelheim, said, "The start of clinical development is an important step toward our goal of bringing BI 4060107 to cancer patients."

This content was produced with the assistance of AI translation services.